News | July 01, 2022
Jubilant HollisterStier announces CAD 100 mn for Montreal facility
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
The settlement and dismissal resolves all claims between the parties
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users
The company is strategically expanding its product portfolio with a pipeline of new products that will form a strong foundation for future growth.
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
The company is now introducing the product into the India pharmaceutical market.
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
Subscribe To Our Newsletter & Stay Updated
